Stocks · News reference

ResMed shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $244 to $262.

Sep 15, 2026, 4:24 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Zacks Investment ResearchSep 15, 2026, 2:10 PMNa
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
Resmed is divesting its MatrixCare business for $490 million to streamline its Residential Care Software segment and focus on higher-growth platforms. The company's Masks segment showed strong 13% revenue growth in fiscal 2026, driven by product innovation and improved compliance rates. However, macroeconomic pressures and intense competition pose operational risks.
RMD VCYT GMED TFX
BenzingaSep 15, 2026, 2:16 PMBenzinga Newsdesk
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262
RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.
RMD
BenzingaSep 8, 2026, 4:05 PMBenzinga News-desk
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.
ABT BAX BDX DXCM GMED